Liquidia Technologies, Inc. (LQDA) shares soared 11.2% in the last trading session to close at $11.15. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% gain over the past four weeks. The sudden rise in the stock price was observed after the United States Supreme Court ruled in favour of Liquidia stating that its pulmonary hypertension treatment powder, Yutrepia, does not infringe upon United Therapeutics' '793 Patent for Tyv ...

Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains rights to Pharmosa's next-generation nebulizers for use with L606 Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America MORRISVILLE, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare ...

MORRISVILLE, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: "Every year, CHEST unites the next generation of medical p ...

Core Viewpoint - Liquidia Corporation has achieved a significant legal victory against United Therapeutics, with the court ruling that United Therapeutics' interference with the launch of generic Treprostinil Injection resulted in losses exceeding $137 million for Liquidia [1][3]. Group 1: Legal Proceedings - The United States District Court for the District of New Jersey found United Therapeutics liable for its actions that interfered with the launch of generic Treprostinil Injection, which is manufactured by Sandoz Inc. [1][2] - Liquidia PAH and Sandoz filed a lawsuit in April 2019, alleging violations of the Sherman Antitrust Act and other unfair competition statutes by United Therapeutics [2][3]. - The court's decision determined that damages caused by United Therapeutics' breach of contract exceeded $137 million, although the final damage award is still pending [3]. Group 2: Financial Implications - Under the agreement between Sandoz and Liquidia PAH, any proceeds from the litigation will be split evenly between the two companies [4]. - Liquidia PAH has entered into litigation finance agreements with Henderson SPV, LLC and PBM RG Holdings, LLC, meaning that any net proceeds from the damage award will be distributed to these parties, leaving Liquidia PAH with no retained proceeds [4]. Group 3: Product Information - Treprostinil Injection is the first-to-file, fully substitutable generic version of treprostinil for parenteral administration, offering the same active ingredients and dosage forms as the branded drug Remodulin® but at a lower price [5]. - Liquidia PAH, in partnership with Sandoz, promotes the appropriate use of Treprostinil Injection for treating pulmonary arterial hypertension (PAH) in the United States [5][6]. Group 4: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a current emphasis on pulmonary hypertension and applications of its proprietary PRINT® Technology [6]. - The company is also developing other formulations of treprostinil, including YUTREPIA™ and L606, while marketing generic Treprostinil Injection [6].

Liquidia Technologies, Inc. (LQDA) shares rallied 14.1% in the last trading session to close at $10.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 33% loss over the past four weeks. The sudden rise in the stock price was observed after Liquidia announced the pricing of an underwritten public offering and a concurrent private placement which is expected to raise gross proceeds of approximately $67.5 milli ...

MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of co ...

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's primary focus includes the development and commercialization of products for pulmonary hypertension and other applications of its proprietary PRINT® Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, which is an investigational drug for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and markets generic Treprostinil Injection for PAH treatment [3] Upcoming Events - Liquidia Corporation will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, from 11:00 – 11:35 a.m. ET [1] - The company will also present at the 2024 Cantor Global Healthcare Conference in New York on September 19, 2024, from 1:30 – 1:50 p.m. ET [1] - Access to the webcasts of these presentations will be available on Liquidia's website [1] Additional Information - An archived version of each presentation will be available on Liquidia's website for at least 30 days following the events [2]

Core Viewpoint - Liquidia Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following a significant stock price drop after FDA news [1][2]. Group 1: Company Developments - On August 19, 2024, Liquidia announced that the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2]. - The company must wait for the expiration of regulatory exclusivity of a competing product before final approval can be granted [2]. - Following this announcement, Liquidia's stock price fell by $4.32 per share, or 30.62%, closing at $9.79 per share on the same day [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Liquidia on behalf of its stockholders [1]. - The investigation focuses on whether Liquidia has violated federal securities laws or engaged in other unlawful business practices [1].

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Liquidia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 19, 2024 ...

Core Viewpoint - Liquidia Corporation has filed litigation against the FDA's decision to grant 3-year new clinical investigation exclusivity to Tyvaso DPI®, which delays the final approval of Liquidia's YUTREPIA™ inhalation powder for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease [1][2] Group 1: Company Actions and Legal Proceedings - Liquidia Corporation has initiated litigation in the U.S. District Court of the District of Columbia to challenge the FDA's exclusivity decision, which it believes stifles competition and patient access to alternative treatments [1][2] - The FDA granted tentative approval for YUTREPIA™ on August 16, 2024, but the exclusivity awarded to Tyvaso DPI delays its final approval until May 23, 2025 [1] - United Therapeutics voluntarily dismissed its complaint against the FDA regarding Liquidia's amended NDA for YUTREPIA, allowing the FDA to proceed with the review [3] Group 2: Product Information - YUTREPIA™ is an inhaled dry-powder formulation of treprostinil designed for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [7][9] - The product utilizes Liquidia's PRINT® technology, which allows for precise and uniform drug particle development, enhancing lung deposition [7] - Liquidia is conducting ongoing clinical studies, including the ASCENT trial, to evaluate the safety and tolerability of YUTREPIA in patients with PH-ILD [8] Group 3: Market Context - Pulmonary arterial hypertension (PAH) affects an estimated 45,000 patients in the U.S., with no current cure, making symptom management and quality of life improvement critical [5] - Pulmonary hypertension associated with interstitial lung disease (PH-ILD) has a prevalence of over 60,000 patients in the U.S., with many underlying conditions underdiagnosed [6]